Tezepelumab-ekko (Monograph)

Brand name: Tezspire
Drug class: Respiratory Tract Agents, Miscellaneous

Medically reviewed by Drugs.com on Dec 17, 2023. Written by ASHP.

Introduction

Human IgG₂ lambda immunoglobulin monoclonal antibody; thymic stromal lymphopoietin (TSLP) blocker.

Uses for Tezepelumab-ekko

Asthma

Add-on maintenance treatment of adult and adolescents ≥12 years of age with severe asthma.

Not indicated for treatment of acute bronchospasm or status asthmaticus. Patients should seek medical advise if their asthma remains uncontrolled or worsens after treatment with tezepelumab.

Several clinical practice guidelines on asthma management are available, including the Global Initiative for Asthma (GINA) guideline. In GINA, stepwise approach to treatment is recommended where specific drugs are added or adjusted up or down through a series of steps (1 through 5) to achieve symptom control while keeping the patient on the lowest effective treatment.

Biologic agents such as tezepelumab are generally recommended as add-on therapy for severe asthma.

Tezepelumab-ekko Dosage and Administration

General

Pretreatment Screening

• Treat preexisting helminth infections prior to initiating therapy.

Patient Monitoring

• Monitor patients for signs and symptoms of hypersensitivity reactions.

Other General Considerations

• Concomitant oral or inhaled corticosteroids should not be discontinued abruptly. If appropriate, reduction in corticosteroid dosage should be done gradually and under the direct supervision of a physician.

Administration

Sub-Q Administration

Available as single-dose vial, single-dose prefilled syringe, or single-dose prefilled pen.

Vials and prefilled syringes are intended for administration by a healthcare provider. Prefilled pens may be administered by a healthcare provider or patient/caregiver after proper training in sub-Q injection technique and after the healthcare provider determines it is appropriate.

Allow product to reach room temperature before administration. This takes about 60 minutes once removed from refrigeration. Do not shake or expose to heat.

Visually inspect contents of vial or prefilled syringe or pen for particulate matter and discoloration prior to administration. Do not use if liquid is cloudy, discolored, or contains large particles or foreign particulate matter.

Inject entire contents of vial or prefilled pen or syringe sub-Q into the thigh, or abdomen, except for the 2 inches around the navel. The upper arm can also be used if a healthcare provider or caregiver administers the injection. Rotate injection sites. Do not inject into tender, bruised, erythematous, or hardened skin areas.

If a dose is missed, administer the dose as soon as possible. Resume regular dosing on the usual day of administration. If the next dose is already due, administer as planned.

Administration of the Prefilled Syringe

Pinch the skin gently and administer the prefilled syringe subcutaneously at an approximately 45° angle into recommended injection site.

Inject all of the drug by pushing plunger until it is completely between the needle guard activation clips. This is necessary to activate the needle guard.

After injection, maintain pressure on plunger head and remove needle from the skin. Release pressure on plunger head to allow needle guard to cover needle.

Administration of the Prefilled Pen

Pinch the skin gently or give the injection without pinching the skin. Position the pen by placing orange needle guard flat against the skin at a 90° angle. Press down firmly until orange needle guard is visible. First click signals that injection has started. Hold down firmly for about 15 seconds; second click will indicate that injection has finished. The orange plunger will fill the viewing window. After injection, lift the pen straight up. The orange needle guard will slide down and lock into place over the needle.

Dosage

Pediatric Patients

Asthma

Sub-Q

Adolescents ≥12 years of age: 210 mg once every 4 weeks.

Adults

Asthma

Sub-Q

210 mg once every 4 weeks.

Special Populations

Hepatic Impairment

Manufacturer makes no specific dosage recommendations.

Renal Impairment

Manufacturer makes no specific dosage recommendations.

Geriatric Patients

Manufacturer makes no specific dosage recommendations.

Related/similar drugs

Tezspire, Fasenra, Trelegy Ellipta, prednisone, Breo Ellipta, Xopenex, Xolair

Cautions for Tezepelumab-ekko

Contraindications

• Known history of hypersensitivity to the drug or any ingredient in the formulation.

Warnings/Precautions

Hypersensitivity Reactions

Hypersensitivity reactions (e.g., rash, allergic conjunctivitis, anaphylaxis) can occur following administration of tezepelumab within hours of administration, but in some instances have a delayed onset (i.e., days).

Consider benefits and risks for the individual patient to determine whether to continue or discontinue treatment.

Acute Asthma Symptoms or Deteriorating Disease

Not indicated to treat exacerbations. Do not use tezepelumab to treat acute bronchospasm or status asthmaticus. Advise patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with tezepelumab.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with tezepelumab. Reductions in corticosteroid dosage, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dosage may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

Unknown response to treatments for helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with tezepelumab. If patients become infected while receiving treatment with tezepelumab and do not respond to antihelmintic treatment, discontinue treatment with tezepelumab until infection resolves.

Live Attenuated Vaccines

Avoid use of live attenuated vaccines in patients receiving tezepelumab.

Specific Populations

Pregnancy

No available data on tezepelumab-ekko use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Placental transfer of monoclonal antibodies such as tezepelumab is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy. No fetal harm observed in animal reproduction studies.

Lactation

Not known whether tezepelumab is distributed into human milk, or if the drug has any effects on the breastfed infant or on milk production. The drug has been detected in animal milk. Tezepelumab is a human monoclonal antibody IgG₂ lambda, and IgG is present in human milk in small amounts.

Consider developmental and health benefits of breast-feeding along with the mother's clinical need for tezepelumab and any potential adverse effects on the breast-fed infant from the drug or underlying maternal condition.

Pediatric Use

Safety and efficacy of tezepelumab-ekko for add-on maintenance treatment of severe asthma have been established in pediatric patients 12–17 years of age. The safety profile and pharmacodynamic responses in pediatric patients were generally similar to the overall study population.

Safety and effectiveness in patients <12 years of age not established.

Geriatric Use

No overall differences in safety or effectiveness observed between patients ≥65 years of age and younger patients.

Hepatic Impairment

Since tezepelumab is not metabolized by hepatic-specific enzymes, changes in hepatic function are not expected to influence the drug's clearance.

Renal Impairment

Clearance does not appear to be affected by mild or moderate renal function. No information available in patients with severe renal impairment.

Common Adverse Effects

Adverse effects (≥3%): pharyngitis, arthralgia, back pain.

Drug Interactions

No formal drug interaction studies performed.

Not metabolized by hepatic enzymes.

Leukotriene Receptor Antagonists

Based on population pharmacokinetic analysis, co-administered asthma medications, including leukotriene receptor antagonists, did not have a clinically meaningful effect on tezepelumab clearance.

Theophylline/Aminophylline

Based on population pharmacokinetic analysis, co-administered asthma medications, including theophylline/aminophylline, did not have a clinically meaningful effect on tezepelumab clearance.

Oral and Inhaled Corticosteroids

Based on population pharmacokinetic analysis, co-administered asthma medications, including oral and inhaled corticosteroids, did not have a clinically meaningful effect on tezepelumab clearance.

Live Attenuated Vaccines

The concomitant use of tezepelumab and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving tezepelumab.

Tezepelumab-ekko Pharmacokinetics

Absorption

Time to peak plasma concentrations achieved in approximately 3 to 10 days.

Steady state: 12 weeks when administered every 4 weeks.

Bioavailability

77%.

Onset

Administration every 4 weeks reduced blood eosinophil counts, FeNO, and concentrations of IL-5 and IL-13 from baseline with an onset 2 weeks after initiation.

Elimination

Half-life

Approximately 26 days.

Elimination Route

Eliminated by intracellular catabolism. Also degraded by proteolytic enzymes that are widely distributed in the body.

Special Populations

Pharmacokinetics not formally studied in patients with hepatic impairment or severe renal impairment (Cl_cr <30 mL/minute). Drug clearance was similar in patients with normal renal function and mild to moderate renal impairment (Cl_cr >30 mL/minute).

Age, sex, and race did not have a clinically meaningful effect on pharmacokinetics.

Higher body weight was associated with lower drug exposure; however, no impact on efficacy or safety was observed.

Stability

Storage

Parenteral

Single-use vial, prefilled syringe or pen for sub-Q administration

Store refrigerated (2–8°C). Keep in original package to protect from light. Do not shake or expose to heat; do not freeze.

May be stored at room temperature (20–25°C) for a maximum of 30 days. Do not return to refrigerator once the drug has been stored at room temperature.

Actions

• Binds to human thymic stromal lymphopoietin (TSLP) and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in the asthma inflammatory cascade.

• Reduces biomarkers and cytokines associated with inflammation including blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13.

• Mechanism of tezepelumab action in asthma has not been definitively established.

Advice to Patients

• Advise the patient to read the FDA-approved patient labeling (patient information).

• Inform patients that hypersensitivity reactions (e.g., rash, allergic conjunctivitis, anaphylaxis) can occur following administration of tezepelumab. These reactions can occur within hours of administration, but in some instances have a delayed onset (i.e., days). Instruct patients to contact their healthcare provider if they experience symptoms of an allergic reaction.

• Inform patients that tezepelumab does not treat acute asthma symptoms or acute exacerbations. Instruct patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with tezepelumab.

• Inform patients to not discontinue systemic or inhaled corticosteroids except under the direct supervision of a healthcare provider. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

• Instruct patients to inform the healthcare provider that they are taking tezepelumab prior to a potential vaccination.

• Advise patients to refrigerate tezepelumab at 2-8°C. Tezepelumab may be kept at room temperature between 20-25°C for a maximum of 30 days. Inform patients and caregivers of the need for proper disposal of the prefilled pen after use, including the use of a sharps disposal container.

• Advise women to inform their clinician if they are or plan to become pregnant or plan to breast-feed.

• Advise patients to inform their clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.

• Advise patients of other important precautionary information.

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Tezepelumab-ekko can only be obtained through designated specialty pharmacies. Contact the manufacturer for specific availability information.

Reload page with references included

Frequently asked questions

• How do I use the Tezspire pen?

Medical Disclaimer